Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Segmentation, By Types (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Target Antigen (CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, Egfrvlll, and Others), Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasts, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular, Carcinoma, Colorectal Cancer, and Others) – Industry Trends and Forecast to 2031
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Analysis
The chimeric antigen receptor (CAR)-T cell therapy market has witnessed remarkable advancements, driven by innovative research and clinical applications. CAR-T cell therapy, which modifies a patient’s T cells to target and attack cancer cells, has shown significant efficacy in treating various hematologic malignancies, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma. Recent developments include the introduction of novel CAR-T products, enhanced manufacturing processes, and the exploration of new target antigens, leading to improved patient outcomes. For instance, companies such as Max Healthcare have launched CAR-T therapies in collaboration with institutions, expanding access to these transformative treatments. In addition, increased investment in clinical trials across regions, particularly in North America and Asia-Pacific, is fostering a competitive landscape, prompting further innovation. As the therapy continues to gain traction, regulatory bodies are adapting to expedite approval processes, facilitating quicker access to life-saving treatments. This dynamic market environment is poised for robust growth, offering promising opportunities for healthcare providers, patients, and pharmaceutical companies alike, as the focus shifts towards expanding indications and improving treatment modalities in CAR-T therapy.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size
The global chimeric antigen receptor (CAR)-T cell therapy market size was valued at USD 2.44 billion in 2023 and is projected to reach USD 5.97 billion by 2031, with a CAGR of 11.80% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends
“Rising Shift Towards Allogeneic CAR-T Cell Therapies”
The chimeric antigen receptor (CAR)-T cell therapy market has witnessed remarkable advancements, driven by innovative research and clinical applications. One prominent trend in the chimeric antigen receptor (CAR)-T cell therapy market is the shift towards allogeneic CAR-T cell therapies, which utilize genetically modified T cells from healthy donors rather than the patient's own cells. Such approach aims to enhance accessibility and reduce the manufacturing time and costs associated with autologous therapies. For instance, companies such as Allogene Therapeutics are developing off-the-shelf CAR-T therapies that can be readily available for patients, minimizing the wait time for treatment initiation. The convenience of allogeneic CAR-T therapies may significantly improve patient outcomes, especially in urgent cases where time is critical, such as acute lymphoblastic leukemia. In addition, ongoing clinical trials and regulatory support are driving innovation in this segment, making allogeneic CAR-T cell therapies a focal point for future advancements in cancer treatment and expanding the market's potential reach across diverse patient populations.
Report Scope and Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Segmentation
|
Attributes
|
Chimeric Antigen Receptor (CAR)-T Cell Therapy Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Autolus Therapeutics (U.K.), CARsgen Therapeutics Holdings Limited (U.K.), Bristol-Myers Squibb Company (U.S.), Sorrento Therapeutics, Inc. (U.S.), bluebird bio, Inc. (U.S.), Eureka Therapeutics Inc. (U.S.), Avacta Group plc (U.K.), Cibus Inc. (France), Celyad Oncology SA (Belgium), Fortress Biotech, Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), Alaunos Therapeutics, Inc. (U.S.), and Poseida Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Definition
Chimeric antigen receptor (CAR)-T cell therapy is an innovative form of immunotherapy that involves genetically modifying a patient's T cells to express chimeric antigen receptors. These receptors are designed to recognize specific antigens present on the surface of cancer cells. Once the T cells are modified, they are expanded in the laboratory and then infused back into the patient, where they seek out and attack the cancer cells, thereby enhancing the body’s immune response against tumors. This therapy has shown significant effectiveness in treating certain hematologic cancers, such as acute lymphoblastic leukemia and non-Hodgkin lymphoma, and is being investigated for use against various solid tumors and other malignancies.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Dynamics
Drivers
- Rising Incidence of Cancer
The global rise in cancer cases has significantly increased the demand for Chimeric Antigen Receptor (CAR)-T cell therapy among healthcare providers treating cancer patients. According to the Centers for Disease Control and Prevention (CDC), in 2019, the United States reported 1,752,735 new cancer diagnoses and 599,589 cancer-related deaths. This translates to approximately 439 new cancer cases and 146 cancer deaths for every 100,000 individuals in the population. The alarming prevalence of cancer is driving healthcare providers to increasingly adopt CAR-T cell therapy due to its numerous benefits, including targeted treatment and personalized approaches, which are expected to further propel market growth. This trend underscores the therapy's potential as a vital component in the fight against cancer, ultimately enhancing patient outcomes and survival rates.
- Rising Product Approvals
The increasing number of product approvals significantly contributes to the growth of the chimeric antigen receptor (CAR)-T cell therapy market. For instance, the approval of CARVYKTI by the Janssen Pharmaceutical Companies of Johnson & Johnson in 2022, which received U.S. FDA clearance for treating adults with relapsed or refractory multiple myeloma (RRMM) who have undergone four or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Such advancements in approvals not only enhance treatment options for patients but also reinforce the market's momentum by encouraging further investment and research in CAR-T cell therapies. Consequently, the growing trend of product approvals is expected to be a significant driver of market growth in this sector.
Opportunities
- Rising Investments from Key Organizations
The growing investments in chimeric antigen receptor (CAR-T) cell therapy are significantly driving market expansion. For instance, in 2021, Blackstone announced that funds managed by Blackstone Life Sciences committed USD 250 million to establish a new company focused on both autologous and allogeneic universal CAR-T cell therapies, collaborating with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH. This substantial financial backing is expected to accelerate research and development efforts, ultimately leading to innovative therapies and improved treatment options for patients. Such investments enhance the therapeutic landscape and represent a significant market opportunity, as they pave the way for advancements in CAR-T cell therapies that can address unmet medical needs and improve patient outcomes.
- Increasing Cases of Multiple Myeloma
The rising incidence of multiple myeloma is projected to drive significant growth in the market for chimeric antigen receptor (CAR)-T cell therapies. According to GLOBOCAN 2020, approximately 176,000 new cases of multiple myeloma and immunoproliferative diseases were expected in 2020, with projections suggesting this figure could soar to 290,000 by 2040. Furthermore, the data indicates that individuals have a 1 in 117 chance of being diagnosed with multiple myeloma by the age of 85. This increasing prevalence highlights a critical market opportunity for CAR-T cell therapies, as healthcare providers seek innovative treatment options to address the growing patient population. The anticipated rise in cases underscores the urgent need for effective therapies, driving demand for CAR-T solutions that can offer improved outcomes for patients suffering from this challenging condition.
Restraints/Challenges
- Adverse Effects of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapies are associated with significant side effects that can hinder market growth. One of the most critical challenges is the occurrence of cytokine release syndrome (CRS), which has been identified as one of the most common and severe adverse reactions to these treatments. CRS results from the rapid activation and proliferation of CAR T-cells, leading to the release of large quantities of cytokines, which are chemical messengers that modulate immune responses. This uncontrolled release can cause symptoms ranging from mild flu-like effects to severe, life-threatening complications such as high fever, low blood pressure, and multi-organ failure. In addition, the mass destruction of antibody-producing B cells can leave patients vulnerable to infections, further complicating their treatment journey. These serious side effects pose significant challenges for healthcare providers and patients alike, potentially limiting the widespread adoption of CAR T-cell therapies and restraining overall market growth.
- Significant Expenses Related to Chimeric Antigen Receptor (CAR)-T Cell Therapy
The substantial costs associated with CAR T-cell therapy pose a significant challenge to market growth, as they can restrict access for many patients who need this advanced treatment. The price of a single CAR T-cell therapy treatment can be exceptionally high, making it unaffordable for a large segment of the population, particularly those without adequate insurance coverage. This financial barrier limits patient access and places an enormous strain on healthcare systems, which must allocate resources to cover these expensive treatments. As a result, disparities in treatment availability may emerge, with wealthier patients gaining access while others are left without options, ultimately hindering the broader adoption and equitable distribution of CAR T-cell therapies. This situation highlights the challenge of integrating these cutting-edge therapies into standard care pathways.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Scope
The market is segmented on the basis of types, target antigen, and therapeutic application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Types
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- Others
Target Antigen
- CD 19
- CD 20
- GD2
- CD22
- CD30
- CD33
- HER1
- HER2
- Meso
- Egfrvlll
- Others
Therapeutic Application
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Leukemia
- Multiple Myeloma
- Pancreatic Cancer
- Neuroblastoma
- Breast Cancer
- Acute Myeloid Leukemia
- Hepatocellular Carcinoma
- Colorectal Cancer
- Others
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, types, target antigen, and therapeutic application as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the chimeric antigen receptor (CAR)-T cell therapy market, driven by a strong foundation in research and commercialization. The region's advanced healthcare infrastructure and investment in innovative therapies contribute significantly to this dominance. Furthermore, the surge in clinical trials focused on T-cell therapies is expected to bolster market growth in North America throughout the forecast period.
Asia-Pacific region is anticipated to experience significant growth in the chimeric antigen receptor (CAR)-T cell therapy market, primarily due to the highest number of registered clinical trials related to these therapies. Governments in the region are making substantial investments and implementing reforms to enhance healthcare infrastructure, which will further stimulate market expansion. As these initiatives progress, they are expected to create a more favorable environment for the development and adoption of CAR-T cell therapies in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Leaders Operating in the Market Are:
- Autolus Therapeutics (U.K.)
- CARsgen Therapeutics Holdings Limited (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Sorrento Therapeutics, Inc. (U.S.)
- bluebird bio, Inc. (U.S.)
- Eureka Therapeutics Inc. (U.S.)
- Avacta Group plc (U.K.)
- Cibus Inc. (France)
- Celyad Oncology SA (Belgium)
- Fortress Biotech, Inc. (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Novartis AG (Switzerland)
- Alaunos Therapeutics, Inc. (U.S.)
- Poseida Therapeutics, Inc. (U.S.)
Latest Developments in Chimeric Antigen Receptor (CAR)-T Cell Therapy Market
- In December 2023, Max Healthcare successfully introduced CAR-T cell therapy in the Delhi-NCR area, marking a significant advancement in cancer treatment options. This innovative therapy, developed in partnership with ImmunoACT, is specifically designed to combat lymphomas and leukemias, offering new hope for patients battling these challenging conditions
- In December 2022, CARsgen Therapeutics Co., Ltd. partnered with the Shanghai Cancer Institute to develop new technology that significantly enhances the antitumor effectiveness of T cells. Their research team discovered that CAR T cells engineered to overexpress Runx3 exhibited sustained antitumor activity and improved tumor control compared to traditional chimeric antigen receptor T-cell therapies
- In November 2022, Caribou Biosciences, Inc. announced that its allogeneic anti-CD19 CAR-T cell therapy, CB-010, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory large B cell lymphoma (LBCL), as well as fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma
- In June 2022, The University of Ottawa showcased promising results from the Canadian-Led Immunotherapies in Cancer-01 (CLIC-01) clinical trial, which focused on one of the first Canadian-developed CAR-T cell therapies for cancer. This therapy features a unique manufacturing process that may lead to more affordable and equitable treatment options
- In November 2021, The California Institute for Regenerative Medicine's governing board approved a grant of USD 4.1 million to support the advancement of innovative chimeric antigen receptor T-cell therapy being developed by scientists at the University of California San Diego School of Medicine, aiding their efforts to transition this promising cancer treatment from the laboratory to clinical practice
SKU-